Trial · NCT05440656
A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.
NCT05440656, Completed, AstraZeneca
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab. Trials, record NCT05440656. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05440656
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.
- NCT number
- NCT05440656
- Status
- Completed
- Enrollment
- 152 participants, actual
- Lead sponsor
- AstraZeneca
- Conditions
- Severe Eosinophilic Asthma
- Interventions
- Cohort
- First posted
- 2022-07-01
- Last updated
- 2026-04-15
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in St. George's Respiratory Questionnaire (SGRQ) | 16 weeks after the initiation of the treatment | Estimation of the proportion of patients achieving a minimum clinically important improvement in respiratory health status (≥ 4-point reduction from baseline in SGRQ total score) in SEA patients initiated on benralizumab |
| Secondary | Change in St. George's Respiratory Questionnaire (SGRQ) | 16 weeks after the initiation of the treatment | Estimation of the proportion of patients achieving a moderately efficacious change in respiratory health status (≥ 8-point reduction from baseline in SGRQ total score) |
| Secondary | Change in St. George's Respiratory Questionnaire (SGRQ) | after 4, 8, 32 and 48 weeks of treatment | Estimation of the proportion of patients achieving a minimum clinically important improvement (≥ 4-point reduction in baseline SGRQ total score) and of those achieving a moderately efficacious change in respiratory health status (≥ 8-point reduction in baseline SGRQ total score) |
| Secondary | Change in St. George's Respiratory Questionnaire (SGRQ) | after 4 and 48 weeks of treatment | Determination of predictors of early clinically important improvement in respiratory health status (measured by the SGRQ) at 4 weeks of treatment with benralizumab, and at 48 weeks post-benralizumab initiation among the 4-week SGRQ responders |
| Secondary | Change in ACQ-6 | after 4, 8, 16, 32, and 48 weeks of treatment | Change in asthma control and the response rate as well as the response rate at 48 weeks post-benralizumab initiation among the 16-week ACQ-6 responders |
| Secondary | Change in the annual rate of clinically significant exacerbations | between the 48-week periods pre- and post-benralizumab initiation | Change in the annual rate of clinically significant exacerbations (CSE) and identification of factors influencing the CSE rate |
| Secondary | change in asthma-related hospital-based health care resource utilization (HCRU) | between the 48-week periods pre- and post-benralizumab initiation | Change in asthma-related hospital-based health care resource utilization (HCRU) |
| Secondary | Change from baseline in clinic-measured spirometric lung function indices | after 16 and 48 weeks of benralizumab treatment | Change from baseline in clinic-measured spirometric lung function indices and description of the FEV1 improvement rate at 48 weeks post-benralizumab initiation among patients who will achieve clinically meaningful improvement in FEV1 at 16 weeks post-benralizumab initiation |
| Secondary | change from baseline in rescue medication use and in the proportion of nights with awakenings due to asthma requiring rescue medication use | after 4, 8, 16, 32 and 48 weeks of treatment | Change from baseline in rescue medication use and in the proportion of nights with awakenings due to asthma requiring rescue medication use |
| Secondary | change in cumulative oral corticosteroid (OCS) burden | etween the 16-week periods pre- and post-benralizumab initiation and the 48-week periods pre- and post-benralizumab initiation | Change in cumulative oral corticosteroid (OCS) burden |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05440656
GET https://conductscience.org/api/trials/v1/NCT05440656/registered